Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation
FEBS Open Bio · 2025-05 · 15 (5) · 836-855
DOI: 10.1002/2211-5463.13970 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Open Bio, online erschienen am 30.01.2025. Verfasst von David Barthélémy und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology-Physiology-Toxicology, Institute of Pharmaceutical and Biological Sciences of Lyon, University Claude Bernard Lyon 1, Fran…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Acrylamides, Aniline Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Inovotion France, AstraZeneca France.
Abstract (Originalsprache)
Non‐small cell lung cancer (NSCLC) affects 10–50% of patients with epidermal growth factor receptor ( EGFR ) mutations. Osimertinib is a third‐generation EGFR tyrosine kinase inhibitor (TKI) that radically changes the outcome of patients with tumors bearing EGFR sensitizing or EGFR T790M resistance mutations. However, resistance usually occurs, and new therapeutic combinations need to be explored. The chorioallantoic membrane (CAM) xenograft model is ideal for studying aggressive tumor growth and the responses to complex therapeutic combinations due to its vascularization and complex microenvironment. This study aims to demonstrate the relevance of analyzing a complex therapeutic response to osimertinib treatment, especially through advanced transcriptomic analysis with the CAM model, which has been limited thus far. We engrafted HCC827 cells ( EGFR p.E746_A750del) into the CAM model and treated them with various osimertinib doses for 7 days. The study involved supervised multivariate discrimination and ontology analysis of human transcriptional data. We found that CDX tumor growth inversely correlated with osimertinib dosage, with a notable 35% tumor weight reduction at 10 μ m . Transcriptomic analysis revealed that osimertinib reduces EGFR pathway activity and its effectors, and dampens chemotaxis, immune recruitment and angiogenesis, indicating that effectiveness extends beyond cellular mechanisms to the tissue level. This was supported by a 15% reduction in blood vessels around the xenograft in osimertinib‐treated cases. This study is the first to demonstrate that ontological analysis of transcriptomic data in the CAM model aligns with clinical observations, highlighting the relevance of this methodology for understanding and ameliorating the efficacy of targeted therapy in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology-Physiology-Toxicology, Institute of Pharmaceutical and Biological Sciences of Lyon, University Claude Bernard Lyon 1, France.
- Department of Biochemistry and Molecular Biology, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France.
- Center for Innovation in Cancerology of Lyon (CICLY) Research Unit 3738, Faculty of Medicine and Maieutic Lyon Sud, University Claude Bernard Lyon 1, Oullins, France.
- INSERM U1052-CNRS UMR5286, Comprehensive Cancer Center Léon Bérard, Cancer Research Center of Lyon, Institut Convergence Plascan, University Claude Bernard Lyon 1, France.
- INOVOTION, La Tronche, France.
- Department of Acute Respiratory Disease and Thoracic Oncology, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France.
ORCID-Profile: David Barthélémy, Arnaud Vigneron, Sébastien Couraud, Léa Payen
Förderung
- Inovotion France
- AstraZeneca France
Zitieren
APA
Barthélémy, D., Vigneron, A., Rousset, X., Guitton, J., Grolleau, E., Raffin, M., Balandier, J., Lescuyer, G., Bardou, M., Geiguer, F., Couraud, S., Bardel, C., Viallet, J., Benzerdjeb, N., & Payen, L. (2025). Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation. FEBS Open Bio, 15(5), 836-855. https://doi.org/10.1002/2211-5463.13970
Vancouver
Barthélémy D, Vigneron A, Rousset X, Guitton J, Grolleau E, Raffin M, et al. Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation. FEBS Open Bio. 2025;15(5):836-855. doi:10.1002/2211-5463.13970
BibTeX
@article{Barthlmy2025,
author = {Barthélémy, David and Vigneron, Arnaud and Rousset, Xavier and Guitton, Jérome and Grolleau, Emmanuel and Raffin, Margaux and Balandier, Julie and Lescuyer, Gaëlle and Bardou, Mathilde and Geiguer, Florence and Couraud, Sébastien and Bardel, Claire and Viallet, Jean and Benzerdjeb, Nazim and Payen, Léa},
title = {Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation},
journal = {FEBS Open Bio},
year = {2025},
volume = {15},
number = {5},
pages = {836--855},
doi = {10.1002/2211-5463.13970}
}
EUVIMED